Stockreport

Your Daily Pharma Scoop: Motif Bio NDA Under Review, MiMedx Nixed, Biogen Halts [Seeking Alpha]

MOTIF BIO PLC ADRS  (MTFB) 
US:NASDAQ Investor Relations: ir.motifbio.com
PDF Summary Stocks in News: MTFB, MDXG FDA accepts Motif Bio's NDA with priority review for Iclaprim Discussion : FDA accepted for filing the NDA of Motif Bio’s [Read more]